End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
21.11 CNY | +0.19% | -2.49% | -15.22% |
Mar. 18 | Dashenlin Pharmaceutical to Buy Back Up to 200 Million Yuan Shares | MT |
Mar. 05 | Dashenlin Pharmaceutical Plans to Buy Back Up to 200 Million Yuan Worth of Shares | MT |
Sales 2023 * | 24.72B 3.42B | Sales 2024 * | 30.75B 4.25B | Capitalization | 24B 3.32B |
---|---|---|---|---|---|
Net income 2023 * | 1.31B 181M | Net income 2024 * | 1.63B 226M | EV / Sales 2023 * | 0.92 x |
Net cash position 2023 * | 1.37B 189M | Net cash position 2024 * | 1.72B 238M | EV / Sales 2024 * | 0.72 x |
P/E ratio 2023 * |
18.3
x | P/E ratio 2024 * |
14.8
x | Employees | 39,499 |
Yield 2023 * |
2.75% | Yield 2024 * |
3.32% | Free-Float | 33.36% |
1 day | -1.17% | ||
1 week | -2.68% | ||
Current month | -11.43% | ||
1 month | -11.77% | ||
3 months | -16.39% | ||
6 months | -15.89% | ||
Current year | -15.38% |
Managers | Title | Age | Since |
---|---|---|---|
Guo Qiang Ke
CEO | Chief Executive Officer | 42 | - |
Guang Zhi Peng
DFI | Director of Finance/CFO | 42 | 18-05-09 |
Zhi Hui Chen
CHM | Chairman | 46 | 15-05-27 |
Members of the board | Title | Age | Since |
---|---|---|---|
Guo Chang Liu
BRD | Director/Board Member | 61 | 16-08-07 |
Yun Feng Ke
FOU | Founder | 57 | 99-02-11 |
Zhi Hui Chen
CHM | Chairman | 46 | 15-05-27 |
Name | Weight | AuM | 1st Jan change | Investor Rating |
---|---|---|---|---|
0.36% | 4 M€ | -2.96% | ||
0.07% | 1 M€ | +3.49% | - |
Date | Price | Change | Volume |
---|---|---|---|
24-03-27 | 21.11 | +0.19% | 7 593 993 |
24-03-27 | 21.07 | -1.17% | 4,980,531 |
24-03-26 | 21.32 | +0.76% | 4,445,482 |
24-03-25 | 21.16 | -0.70% | 4,702,411 |
24-03-22 | 21.31 | -2.11% | 5,948,041 |
End-of-day quote Shanghai S.E., March 26, 2024
More quotesEPS Revisions
1st Jan change | Capi. | |
---|---|---|
-15.38% | 3.32B | |
-19.49% | 18.13B | |
-29.16% | 11.09B | |
-2.90% | 6.79B | |
-0.60% | 5.57B | |
+10.80% | 5.26B | |
+34.14% | 3.93B | |
-9.43% | 3.75B | |
+4.30% | 3.55B | |
+15.16% | 3.26B |